COVID-19: Antibody cocktail therapy approved as a “preventive drug”: RONA PREVE
-“RONA PREVE” for mildly ill patients-
“Antibody cocktail therapy”:
“Antibody cocktail therapy” is used to treat mildly ill patients with the new coronavirus.
Council of Ministry of Health, Labor and Welfare:
We have agreed to use it as the first “preventive drug” for asymptomatic people.
“RONA PREVE” for mildly ill patients:
Chugai’s “Ronapreve”, which is used for antibody cocktail therapy, has been approved by the council.
Approved as “corona prophylaxis”
In July of this year, it was specially approved as a “therapeutic drug” for mild and moderately ill patients at risk of aggravation.
With the new purpose of “preventing the onset”, the scope of administration will be expanded.
Chugai
In clinical trials
The risk of developing the disease in close contact at home has been reduced by 81 percent.
People who tested positive and were asymptomatic had a 31 percent reduction in their risk of developing the disease.
In addition, antibody cocktail therapy, which is in the form of an intravenous drip, was also approved for subcutaneous injection.
NTV NEWS24
https://www.news24.jp/articles/2021/11/04/07968978.html
Japan to use antibody cocktail to prevent symptoms
Japan’s health ministry
is to expand the use of a so-called antibody cocktail to prevent COVID-19 symptoms in patients’ families and others.
The ministry approved in July
the intravenous use of the antibody cocktail, which combines two types of antibodies, for patients with mild to moderate symptoms that could become severe.
Chugai Pharmaceutical,
the drug’s distributor in Japan,
had applied for expanding its use to include prevention.The company cited the results of overseas clinical trials
that show an 81 percent reduction in the risk of symptomatic coronavirus infections among people who were in close contact with infected family members.
On Thursday,
an expert panel approved the ministry’s policy to use the antibody cocktail for household exposure and asymptomatic cases.But it added that
the use in principle must be limited to those who are at risk of developing severe symptoms if infected.The panel stressed that
vaccination is the first line of defense for any infectious disease and limited the cocktail’s use to those who may not fully benefit from vaccination.It also agreed to subcutaneous administration, which takes less time than intravenous infusion.
The ministry is set to give formal approval on Friday,
after which the antibody cocktail will be the first drug approved in Japan to prevent COVID-19 symptoms.
NHK WORLD-JAPAN News